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ORIGINAL RESEARCH
Genetic Testing Reveals Germline Mutations Among Patients 
Undergoing Surgery for Colorectal Carcinoma in a Community 
Hospital Setting
Alex Jones, MD2, Dana Greer, RN, BSN, OCN¹, Karin L Cole, MD1,2
1Northern Light Mercy Surgery, Portland, ME,  2Tufts School of Medicine, Boston, MA
Introduction: Defined germline mutations contribute to 5% to 10% of cases of colorectal carcinoma (CRC). While 
protocols for universal tumor screening have been adopted to detect mismatch repair (MMR) protein 
deficiency, widespread multigene panel testing has not been achieved. Barriers to implementing testing 
protocols may occur in community settings.
Methods: A total of 160 patients presenting for surgical management of CRC between 2011 and 2020 were 
considered for retrospective analysis in a single-surgeon, single-institution, community-based cohort. 
The rate of multigene panel testing and prevalence of germline mutations were calculated, and patient 
characteristics were assessed.
Results: A total of 32/160 (20%) patients underwent multigene panel testing, with 14/160 (9%) patients having 
germline mutations. While 88% of patients underwent panel testing after CRC diagnosis, 43% of these 
patients would have met testing criteria before diagnosis. Among the patients meeting criteria before 
diagnosis, 50% were found to carry a germline mutation.
Discussion:  The prevalence of germline mutations was similar to previously reported values, while the rate of 
multigene panel testing was higher than previously reported. These results may be unique to the study 
setting or result from multidisciplinary conference discussion. A significant number of patients with 
abnormal panel testing were not tested before CRC diagnosis, despite meeting the criteria. This finding 
represents a missed opportunity for risk stratification and underscores the importance of addressing 
testing barriers in the primary care setting.
Conclusions:  Primary care providers and oncologists in community hospitals must remain cognizant of changing 
guidelines as multigene panel testing becomes increasingly available.
Keywords:  colorectal carcinoma, genetic screening, community hospital, risk stratification
Colorectal carcinoma (CRC) is the third leading cause of cancer-related death worldwide.1 While most cases of CRC occur 
sporadically, heritable factors may be identified in 
20% to 30% of cases, with 5% to 10% of cases 
specifically associated with a defined genetic 
syndrome.2 Colon and rectal cancers represent a 
heterogenous group of malignancies with diverse 
molecular and genetic underpinnings. Interestingly, 
specific genetic changes are associated with tumor 
site3 and distinct tumor behaviors, which inform 
prognosis and options for targeted therapies. In 
some cases, germline mutations give rise to familial 
cancer syndromes with greater lifetime risk of 
developing CRC. Most common among these are 
Lynch Syndrome, characterized by mutations in 
mismatch repair (MMR), and Familial Adenomatous 
Polyposis, characterized by Adenomatous 
Polyposis Coli genes. Recognizing patients with 
such syndromes is particularly important, as future 
risk for patients and their family members can be 
subsequently stratified.
While many health systems have implemented a 
protocol for universal screening of CRC tumor tissue 
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for MMR protein deficiency, the decision to screen 
patients for inherited genetic changes using next-
generation sequencing is more complex. Regulatory 
bodies, such as the National Comprehensive 
Cancer Network (NCCN), have provided guidance 
on which patients with CRC should undergo such 
testing. Although rates of multigene panel testing 
are increasing, many barriers limit the number of 
qualifying patients who actually undergo testing.4, 5 
These barriers may be even more pronounced in the 
community hospital setting.6 We hypothesize that: 
(1) the rate of genetic testing for patients with CRC 
at our community-based institution may be lower 
than in the academic setting; (2) the prevalence 
of germline mutations may be lower in our cohort 
due to testing barriers coupled with a tendency for 
younger, more complex patients (who may be more 
likely to exhibit germline mutations) to be referred to 
large specialty centers; (3) a significant proportion 
of patients undergoing genetic testing after their 
cancer diagnosis would not have met testing criteria 
before diagnosis.
METHODS
A total of 160 patients who underwent surgical 
resection of the colon or rectum for a diagnosis of 
CRC between 2011 and 2020 were considered for 
inclusion in the retrospective analysis. Surgeries 
were performed by a single surgeon (KC), who is 
responsible for all elective CRC surgeries at Mercy 
Hospital in Portland, Maine. Characteristics of these 
patients, including basic demographics, cancer 
location and stage, results of MMR deficiency 
testing, and results of multigene panel testing, were 
abstracted from a colorectal surgery database that 
is prospectively maintained. This database was 
approved by the institutional review board at Mercy 
Hospital (protocol 137) for research purposes, and 
patients enrolled after the approval date provided 
informed consent. Additional chart review was 
performed to obtain detailed data on family history.
As part of routine pathologic analysis, staining of 
tumor tissue for MMR proteins was performed, 
and tumors with MMR protein deficiency reflexed 
to MLH1 promoter hypermethylation and BRAF 
mutation studies. MMR deficiency can occur in 
sporadic cases of CRC, specifically with lost MLH1 
expression due to somatic hypermethylation of the 
MLH1 promoter or with BRAF V600E mutations.7 
Hence, patients with either MLH1 promoter 
hypermethylation or BRAF V600E mutations were 
considered to have MMR deficiency that was 
somatic in nature. In these cases, further testing for 
germline mutations was not recommended.
Cases were presented at an institutional 
multidisciplinary cancer conference either at the time 
of diagnosis or after surgery, at which time genetic 
testing considerations were discussed. Patients 
who met NCCN criteria for multigene panel testing 
based on MMR status, personal/family history, or 
polyp burden8 were considered appropriately. The 
cost of testing varied depending on the patient’s 
health insurance plan. Patients facing prohibitively 
high out-of-pocket costs, including those without 
insurance, were helped with applying for financial 
assistance from companies offering testing; this 
cost was often forgiven. Following this counseling, 
patients decided whether to proceed with multigene 
panel testing. This process of selecting patients for 
multigene panel testing is summarized in Figure 1.
For each of the 32 patients undergoing multigene 
panel testing, chart review was conducted to assess 
(1) when testing was conducted relative to CRC 
diagnosis and (2) whether patients would have 
met any NCCN criteria for multigene panel testing 
unrelated to the index cancer diagnosis.8 These 
patients are described as having met diagnosis-
independent criteria (DIC). Descriptive statistics 
only were used in data analysis.
RESULTS
In this community-based cohort of 160 patients 
presenting for surgical management of CRC, 
32 (20%) underwent multigene panel testing for 
germline mutations. The prevalence of germline 
mutations in this cohort was 14/160 (9%) in the 
overall population with CRC, and 14/32 (44%) 
in those undergoing multigene panel testing. 
Compared with 128 patients who did not undergo 
testing, or had negative results, patients with 
germline mutations were more likely to have right-
sided tumors (positive: 50%; negative/untested 
40%) and were younger (positive: 59 years; 
negative/untested: 66 years) at the time of surgery 
(Table1).
In total, 28/32 (88%) patients undergoing multigene 
panel testing were tested only after the diagnosis of 
CRC was given. Testing was positive for 3 patients 
who were tested before diagnosis and for 1 patient 
for whom timing could not be determined. The 
decision to pursue testing was based on results from 
universal screening for MMR protein deficiency in 
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11/32 (34%) patients ultimately undergoing testing. 
Among these patients, 6/11 (55%) harbored a 
germline mutation. Among patients undergoing 
testing based on other factors, 8/21 (38%) patients 
harbored a germline mutation. Among 28 patients 
tested after CRC diagnosis, 12 (43%) would have 
qualified before CRC diagnosis (ie, met DIC). 
Among these 12 patients, 6 tested positive for 
germline mutations (50%) compared to 4/16 (25%) 
patients who did not meet DIC before diagnosis 
(Figure 2). Factors causing these specific patients 
to meet DIC are listed in Table 1. Overall, prior 
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Figure 1: Summary of patient selection for multigene panel testing among the total population presenting 
for surgical management of colorectal carcinoma and breakdown of the corresponding number of patients 
in each sub-cohort. Patients were selected for germline mutation based upon either abnormal universal 
screening for MMR protein deficiency without abnormal BRAF/MLH1 promoter hypermethylation reflex 
testing, or other unrelated clinical factors.
MMR: mismatch repair 
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DISCUSSION
In our community-based cohort of patients 
undergoing surgery for CRC, the prevalence of 
identified germline mutations was 9%, within the 
range of previously reported values.2 Among all 
patients with CRC, 20% underwent multigene panel 
testing. This value is higher than that reported in 
another study among 4 academic centers, wherein 
8.5% of patients with CRC underwent panel testing.9 
These findings suggest that our patients did not 
face disproportionate barriers to testing relative to 
the cohort based in a tertiary care center, or that 
those barriers were addressed. The relatively high 
percentage of patients tested may be because of 
the routine discussion of cases with a genetic testing 
coordinator through multidisciplinary conference, 
or that this was a single-surgeon series, limiting 
variability in practice.” 
Patients with germline mutations were younger 
at the time of surgery than those not harboring 
such mutations. However, these patients were, on 
average, older than those in another study reporting 
a mean age at diagnosis of less than 40 years 
for those with germline mutations.10 Importantly, 
however, this study showed that only 1 in 5 patients 
diagnosed under the age of 50 years carried such 
a mutation, suggesting a significant role for other 
factors in the development of early onset CRC.10 
Our discrepant finding may be due to a small sample 
size, or it may better reflect the demographics 
of patients who present for care in a community 
setting. In either case, we recommend considering 
heritable factors in all patients presenting with CRC, 
regardless of age at diagnosis.
The minority of patients undergoing multigene 
panel testing in our cohort were tested for germline 
mutations based on universal screening for MMR 
protein deficiency (34%). However, these patients 
32 Patients 
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Figure 2: Summary of the timing of testing relative to colorectal carcinoma diagnosis for 32 patients 
undergoing multigene panel testing and results of this testing stratified by whether or not patients met 
diagnosis-independent criteria for testing.
* Each of these patients ultimately exhibited abnormalities on multigene panel testing. 
† These patients represent missed opportunities to identify germline mutation and subsequently risk stratify prior to 
diagnosis.  
CRC: colorectal carcinoma; DIC: diagnosis-independent criteria 
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were more likely (55%) to test positive for a germline 
mutation than patients tested based on other 
factors (38%). This finding is consistent with the 
observation that Lynch Syndrome, caused by MMR 
protein deficiency, is the most common heritable 
cause of CRC.
We found that 50% of cancers were right-sided 
in the cohort of patients with germline mutations 
compared to 40% of those without such mutations. 
This finding is consistent with previous models that 
suggest a continuum of carcinogenesis along the 
gastrointestinal tract. In these models, right-sided 
tumors exhibit a higher degree of BRAF mutations 
and microsatellite instability.3 Based on these 
findings, CRC cases characterized by heritable 
factors, and in particular those demonstrating 
microsatellite instability, are more likely to be right-
sided. Our findings were consistent with this model. 
In our cohort, 2 patients with mutations associated 
with Lynch Syndrome and 2 patients with MUTYH 
mutations, corresponding to a related syndrome, 
developed tumors in the right colon or cecum.
A minority (43%) of patients who underwent 
genetic testing after CRC diagnosis would have 
qualified for testing based on other criteria. An 
opportunity to risk stratify these patients may 
have been missed either because historical 
information was not collected or updated before 
diagnosis, or because this information was not 














1 62 Cecum I Other factors MUTYH x2 Yes Polyps
2 63 Cecum IIC MMR screen-ing VUS in NBN No NA
3* 69 Cecum I Other factors MSH6 Yes Prior cancer
4 64 Right colon I Other factors VUS in ATM No NA
5 68 Rectum IIIB MMR screen-ing MUTYH No NA
6 43 Transverse colon I
MMR screen-
ing MLH1 Yes Family history
7 64 Cecum IIA MMR screen-ing
MUTYH Heterozy-
gous Yes Family history
8* 42 Cecum IIA MMR screen-ing PMS2 Yes Prior cancer
9 60 Transverse colon IIC
MMR screen-
ing MLH1/LYNCH Yes Family history
10 56 Right colon IIIB Other factors CHEK2 Yes Family history
11 66 Rectum I Other factors MSH6 No NA
12 72 Left colon IIIB Other factors VUS in MYH Yes Prior cancer
13* 46 Sigmoid colon IVB Other factors p53 Yes Prior cancer
14* 48 Rectum I Other factors VUS in p53 Yes Prior cancer
CRC, colorectal carcinoma; DIC, diagnosis-independent criteria; MMR, mismatch repair; NA, not applicable; VUS, 
variant of uncertain significance.
*Multigene panel testing conducted before CRC diagnosis or timing could not be determined.
†Presented as either abnormal MMR protein deficiency screening with negative reflex testing for a BRAF mutation 
or MLH1 promoter hypermethylation (suggesting germline deficiency), or other clinical factors independent of MMR 
screening results.
Table 1. General and Genetic Tumor Characteristics for All patients with Abnormalities on Multigene 
Panel Testing
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missed opportunity underscores the importance of 
an approach to genetic counseling that is holistic, 
but also dynamic and adaptable to changing 
personal history, family history, and guidelines. 
In some cases, the failure to properly screen and 
test patients with indications may have clinically 
significant implications. Considering only patients 
who underwent testing after CRC diagnosis among 
our cohort, those who met criteria before diagnosis 
were more likely to subsequently test positive for 
a germline mutation (50%) than those who did not 
meet criteria before diagnosis (25%) (Figure 2). 
For the 6 patients with germline mutations who met 
criteria before diagnosis, earlier genetic testing and 
risk stratification may have resulted in diagnosis at 
a less advanced stage and consequently changed 
management and prognosis.
In addition to risk stratification and enhanced 
cancer screening, identifying inherited cancer 
syndromes before cancer diagnosis supports 
patient counseling regarding future health risks, 
fertility, and other important considerations. These 
benefits highlight the importance of attempting to 
identify these patients in the primary care setting. 
While our study was not designed to evaluate the 
presence of pre-diagnosis testing barriers faced by 
our patients, we suspect several factors may have 
contributed to the missed opportunities to identify 
mutation carriers before diagnosis. Consistently 
identifying patients for multigene panel testing in 
the primary care setting requires that patients have 
a primary care doctor, personal and family history 
of malignancy are updated and reviewed often, and 
primary care providers remain up-to-date on the 
indications for panel testing. These challenges are 
exacerbated by experts who do not agree on which 
patients should qualify for multigene panel testing. 
A position statement on multigene panel testing 
from the Collaborative Group of the Americas on 
Inherited Gastrointestinal Cancer outlines patients 
who are most likely to benefit from testing based 
on available evidence.4 While the NCCN guidelines 
currently provide similar suggestions,8 widespread 
consensus and implementation of corresponding 
protocols has yet to be achieved. Even among 
patients who are appropriately counseled on 
genetic risk and eligibility for testing, patient-
specific factors (eg, insurance status, out-of-pocket 
expenses, education level) may influence the 
decision to proceed. Our institution has seen some 
success in identifying patients for genetic testing 
by eliciting a focused personal and family history 
from patients when they present for breast or CRC 
screening, which reduces the burden on primary 
care providers.
Primary care providers face challenges in identifying 
and managing patients at increased heritable risk 
for cancer. These challenges, including provider-, 
institution-, and society-specific barriers, were 
documented even before widespread availability 
of next-generation sequencing.11 In the case of 
multigene panel testing, implementing protocols for 
risk-assessment, testing, results interpretation, and 
counseling can be difficult, even in subspecialty 
centers. One study used a standardized tool to 
assess clinical risk for CRC at an open-access 
colonoscopy practice. The study demonstrated a 
low rate of referral to cancer genetics centers for 
patients identified as high-risk and a low rate of 
patient follow-through, even in cases when a referral 
was completed.12 A number of factors, similar to 
those encountered in the primary care setting, 
likely contribute to this phenomenon. One particular 
concern for any provider ordering multigene panel 
testing is whether identified mutations will even alter 
clinical decision-making. Our findings indicate that 
screening unaffected individuals in our community-
based cohort could have identified patients at high 
risk before cancer developed or earlier in the course 
of disease. While our study was not designed to 
determine whether earlier diagnosis would have 
improved outcomes, an analogous study among 
patients with breast cancer demonstrated changes 
in medical management for 58% of patients with 
identified mutations on multigene panel testing.13 
If multigene panel testing can provide clinically 
useful information, ordering providers must also be 
capable of applying results to the care of patients 
at high risk, another obstacle to widespread 
implementation of such practices.
Whether in the primary care setting, or a subspecialty 
clinic, addressing challenges with systems-based 
practices may help improve availability of next-
generation sequencing technology to patients 
presenting in the community setting. To this end, 
several suggestions have been proposed, including 
collaboration between non-genetics and genetics 
providers,14 multidisciplinary care coordination in a 
single visit,15 workflow changes,16 risk-assessment 
training and education, practice-based support, 
and opportunities to enroll patients in research 
trials after identifying uncharacterized mutations.5 
While our cohort of patients appeared to face 
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significant barriers to testing before CRC diagnosis, 
they did not face such limitations after diagnosis. 
This result is likely due to the comprehensive 
and multidisciplinary approach to genetic risk-
assessment adopted by our institution.
Our study is limited by the retrospective nature, 
small sample size, and single-surgeon/single-
institution population, each of which limits 
generalizability of our results. In addition, due to 
the limitations inherent to using retrospective data, 
we were unable to determine what proportion of 
patients may have qualified for genetic testing 
but ultimately remained untested due to patient 
preference or financial constraints. A chart review 
of the untested cohort revealed only one patient 
who declined and a few references to the financial 
burden of testing. These issues, therefore, do not 
seem to be common, which is supported by the 
relatively high rate of testing in this cohort compared 
with previous reports. Despite these limitations, 
we were able to document a relatively high rate of 
mutation carriers in our population, some of whom 
would have met criteria for genetic testing before 
their cancer diagnosis. This notion highlights the 
need for improved practices in genetic testing both 
in primary care and subspecialty settings.
CONCLUSIONS
The prevalence of germline mutations among our 
community-based cohort of patients undergoing 
surgery for CRC is similar to previously published 
population-wide values. Patients with germline 
mutations were younger, more likely to have right-
sided tumors, and could not always be identified 
by genetic testing criteria other than the index 
cancer diagnosis. In some cases, however, 
patients had indications for genetic testing before 
diagnosis, representing a missed opportunity to 
identify germline mutations before CRC developed 
or earlier in the disease course. These results 
underscore that subspecialty and primary care 
providers in community settings need to remain 
cognizant of changing guidelines. They also need to 
advocate for systems-based practices that address 
limitations to implementing genetic counseling and 
screening among patients presenting for care, both 
with and without a cancer diagnosis. These efforts 
will become increasingly important as targeted 
therapies and personalized medicine become more 
prevalent.
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